Advanced Cell Therapy product release containing CAR-T cells
DOI:
https://doi.org/10.46765/2675-374X.2022v3n1p156Palavras-chave:
CAR-T cells, product release, potency test, sterility, safetyResumo
Manufacturing of customized gene or cell therapy products such as CAR-T cells is complex and depends on release tests and exams that can attest to a consistent quality standard for each product. The quality of CAR-T cell products is subject to donor variation, but also includes the manufacturing environment, as well as the quality and availability of materials and reagents. Quality must be carefully monitored and integrated into the manufacturing process.
Downloads
Publicado
24/04/2022
Como Citar
Preto de Godoy, J., Nassif Kerbauy, L., Melo Alves Paiva, R., Tiemi Kondo, A., Keith Okamoto, O., & Mauro Kutner, J. (2022). Advanced Cell Therapy product release containing CAR-T cells. JBMTCT, 3(1), 156. https://doi.org/10.46765/2675-374X.2022v3n1p156
Edição
Seção
Artigos
Licença
Copyright (c) 2022 JBMTCT
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
